AIM

Quote

Short

News

Articles

Message Board

AIM ImmunoTech Inc. (NYSE : AIM ) News

AIM ImmunoTech Inc. (NYSE: AIM) News Releases

AIM News Releases

March 06, 2026 07:00:00 pm

GlobeNewswire

AIM ImmunoTech Announces Closing of its Rights Offering

March 05, 2026 07:00:00 am

Canada Newswire

AIMIA TO REPORT FOURTH QUARTER AND FULL YEAR 2025 RESULTS ON MARCH 24

March 04, 2026 09:00:00 am

GlobeNewswire

AIM ImmunoTech Announces Expiration and Preliminary Results of its Rights Offering for Aggregate Gross Proceeds of $1.8 Million

March 02, 2026 09:00:00 am

GlobeNewswire

AIM ImmunoTech Signs Agreement for Planning of a Proposed Phase 3 Clinical Trial of Ampligen in the Treatment of Late-Stage Pancreatic Cancer

February 27, 2026 09:00:00 am

GlobeNewswire

AIM ImmunoTech Reminds Stockholders of March 3, 2026 Expiration Date and Updates Terms of Previously Announced Rights Offering

February 25, 2026 09:00:00 am

GlobeNewswire

AIM ImmunoTech Announces Extension of Subscription Period of its Previously Announced Rights Offering to March 3, 2026

February 23, 2026 08:55:00 am

GlobeNewswire

AIM ImmunoTech Announces Planned Milestones in the Ongoing Phase 2 Trial of Ampligen and AstraZeneca's Durvalumab in the Treatment of Metastatic Pancreatic Cancer

February 17, 2026 09:00:34 am

QM US Market Movers News

US Companies Moving the Markets, Morning edition
Tue, Feb 17, 2026 as of 10.00 am ET

February 12, 2026 04:35:00 pm

GlobeNewswire

CORRECTION: AIM ImmunoTech Announces Commencement of Rights Offering

February 12, 2026 08:55:00 am

GlobeNewswire

AIM ImmunoTech to Participate in Live Virtual Investor Closing Bell Event

Subscribe to Our Newsletter

Download The Market Wire News App

Link Market Wire News to Your X Account